Ovarian Cancer

Vote on the top abstracts and topics to watch in gynecologic and gastrointestinal oncology during the 2025 ESMO Congress.

Experts in the gynecologic cancer landscape highlight their most anticipated presentations ahead of the 2025 ESMO Congress.

Stenoparib monotherapy generated long-term clinical benefit in patients with platinum-resistant and -refractory advanced ovarian cancer.

A United Kingdom Conformity Assessed marking was granted to the Avantect Multi-Cancer Detection Test and Avantect Ovarian Cancer Test.

The top 5 OncLive TV videos of the week cover insights in lung cancer, multiple myeloma, and ovarian cancer.

The FDA held a Type A meeting for RP1 in advanced melanoma, the AACR released its Annual Cancer Progress Report, and more.

Domenica Lorusso, MD, PhD, details the rationale for the ROSELLA trial, evaluating relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.

Updated PYNNACLE data show activity of rezatapopt in TP53 Y220C–mutated solid tumors.

Raludotatug deruxtecan earned FDA breakthrough designation for CDH6-expressing platinum-resistant ovarian cancers after bevacizumab treatment.

The FDA has approved TAR-200 in urothelial cancer and selumetinib in pediatric NF-1–associated inoperable plexiform neurofibromas, and more.

Vanda Salutari, MD, discusses the efficacy of first-line rucaparib maintenance therapy in patients with HRD-negative high-grade, advanced ovarian cancer.

Ryan M. Kahn, MD, MHS, FACOG, discusses the evolution of surgical techniques and practice-changing treatments in the ovarian cancer treatment paradigm.

Kathleen N. Moore, MD, MS, discusses the use of PARP inhibitors in patients with ovarian cancer.

The FDA accepted a NDA for relacorilant in platinum-resistant ovarian cancer based on data from ROSELLA and other phase 2 trials.

Alison Schram, MD, discusses the potential clinical utility of PKMYT1-targeted agents in gynecologic malignancies.

Ryan Matthew Kahn, MD, MHS, FACOG, discusses the importance of recognizing surgical limitations in the treatment of patients with advanced ovarian cancer.

Health Canada approved mirvetuximab soravtansine for folate receptor-alpha positive, platinum-resistant epithelial ovarian cancer.

The top 5 OncLive videos of the week cover insights in lung cancer, ovarian cancer, breast cancer, and prostate cancer.

Fiona Simpkins, MD, discusses the utility of cyclin E1 protein expression as a biomarker to predict response to azenosertib in ovarian cancer.

Stenoparib receives FDA fast track designation for the treatment of patients with advanced ovarian cancer.

Ou Deng, PhD, discusses research aimed at clarifying the role of MSH6 in modulating sensitivity to PARP inhibitors in patients with BRCA-proficient HGSOC

Domenica Lorusso, MD, PhD, discusses the use of relacorilant plus nab-paclitaxel for the treatment of patients with platinum-resistant ovarian cancer.

The top 5 OncLive videos of the week cover insights in renal cell carcinoma, glioma, multiple myeloma, and ovarian cancer.

Alexander B. Olawaiye, MD, discusses future research directions with relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer.

Pamiparib with paclitaxel, carboplatin, and bevacizumab yields high complete cytoreduction rates, manageable safety in advanced ovarian cancer.